Presenter's Information

David Joel Cohen, MD

Country USA
Specialty Interventional Cardiologist
  1. Cerebral Embolic Protection in TAVR: PROTECTED-TAVR and BHF-PROTECT-TAVI
  2. Mechanical Circulatory Support in High-Risk PE
  3. Reducing Infarct Size in STEMI- What Are the Options and Are They Cost-Effective?
  4. Prediction and Prevention of LVOT Obstruction During TMVR
  5. Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: The TAVR UNLOAD Trial
  6. [Debate 2025: Use of Cerebral Embolic Protection in Contemporary TAVR Practice] Not Yet: Futility for Stroke Events
  7. TAVR for Moderate AS and Heart Failure: The TAVR UNLOAD Trial
  8. Innovation in TAVR: What Can We Expect for the Next Decade?
  9. Quality of Life Benefits of Tricuspid Valve Therapies - Insights From the TRILUMINATE Trial
  10. Challenges With Valve-in-Valve TAVR - Role of Bioprosthetic Valve Fracture, Coronary Protection, and Leaflet Modification
  11. PARTNER 3 Low Risk 5 Year Clinical and Echocardiographic Follow-up
  12. Novel Drug-Eluting Stent Designs: Not Yet Plateau, Still Need to Go!!!
  13. Contemporary Best Antiplatelet Strategy in HBR or CHIP Patients: How and What?
  14. Cost-Effectiveness of TEER - Insights From the COAPT Trial
  15. Challenges with ViV TAVR - Role of Bioprosthetic Valve Fracture, Coronary Protection, and Leaflet Modification
  16. Temporal Trends in TAVR Indication and Outcomes - Insights from the US TVT Registry
  17. Optimal Indication for CEP for TAVR: Insights from the STS-TVR and PROTECTED-TAVR
  18. Year-In-Review: Transcatheter Valve Therapy
  19. How Recent Guidelines Will Change the Approach of Mitral Disease Management in the Coming Years
  20. Left Main Revascularization; Consensus and Gaps in 2023
  21. Cost-effectiveness of TMVR (MitraClip)- Insights from the COAPT Trial
  22. Optimal Indication for Cerebral Embolic Protection for TAVR: Insights from the TVT Registry
  23. TAVR Economics and Efficiencies: Insights from the First Decade
  24. Economic Outcomes of TAVR vs SAVR for Low-Risk Patients: Results from the PARTNER 3 Trial
  25. Bioprosthetic Valve Fracture for Optimization of Valve-in-Valve: When, Why, and How?
  26. Composite Outcomes and Net Adverse Events: Implications for Trial Design and Interpretation
  27. COVID-19 and RAAS Inhibitors
  28. Who Should Not Undergo TAVR? Key Insights from the Pivotal Trials and Registries
  29. Quality of Life Outcomes of Transcatheter Mitral Valve Repair: Insights from the COAPT
  30. QOL Outcomes of the COAPT Trial
  31. A Journey of PCSK9 Inhibitors: From Genetics To Clinics
  32. The Emerging Role of NOACs in the Management of Stable CAD and PAD
  33. Failing Bioprosthetic Valves: Valve Fracture, Basilica, and Others
  34. ViV TAVR: The Role of Bioprosthetic Valve Fracture
  35. Valve-in-Valve: TAVR with BVF(Bioprosthetic Valve Fracture): In-Depth Techniques and Updated Data
  36. TAVR: Insights from Quality of Life and Economic Evaluation
  37. Stable CAD & PAD: COMPASS Trial - Will It Change Practice?
  38. PARTNER 2A and SAPIEN 3 Cost-Effectiveness: Cost-effectiveness of TAVR Versus SAVR in Intermediate Risk Patients with Aortic Stenosis
  39. Expanding Role of NOAC in PCI/AF, ACS, and Stable ASCVD: Recent Trials and Next Expectations
  40. Bioprosthetic Valve Fracture for Optimizing the Results of Valve in Valve TAVR
  41. TAVR: Insights from QOL and Economic Evaluation
  42. Selecting the Appropriate Patients for Long-term DAPT; Insights from PEGASUS TIMI-54
  43. ACS and DAPT Duration: Which One and How Long?
  44. TAVR - Year in Review
  45. Finding from PARTNER II Quality of Life Data
  46. What Is the Optimal Duration of DAPT After PCI/DES?
  47. Bioresorbable Vascular Scaffolds and DAPT Duration: The Longer the Better?
  48. Selecting the Appropriate Patients for Long-Term DAPT; Insights from Latest Trials
  49. Extremely High Risk for TAVR - Insights from QOL and Cost-Effectiveness Studies
  50. Optimizing Antiplatelet Therapy: Balancing Ischemic & Bleeding Risks
  51. Pretreatment with P2Y12 Inhibitors: When Selective vs. Routine Is Used?
  52. Cost-Effectiveness and Its Clinical Application
  53. Cost-Effectiveness of PCI for LM Disease
  54. Six Months Enough!
  55. Quality of Life After TAVI: What Do We Know? Why Should You Care?
  56. Guideline Today: Preload Prior to PCI - Standard of Care
  57. Early Insights on Cost-effectiveness
  58. CABG Status 2013: (i) Is Off-pump a Real Option? (ii) Aftermath of FREEDOM Results
  59. Counterpoint: Resisting the Bioabsorbable DES "Bandwagon": A Healthy Dose of Skepticism
  60. Why the Adoption of New Agents Is So Low?
  61. Management Guideline for Ischemic HF
  62. When Is TAVI Not Cost-effective?
  63. How to Overcome the Challenges?: New Agents - Prasugrel
  64. Nuances of Clinical Trials: Trial Size, Power Analysis, Sub Groups
  65. New Thienopyridine Use in ACS and PCI (TRITON-TIMI 38 and Several Subgroup Analyses, PLATO and Several Subgroup Analyses, and CHAMPION Trials)
  66. Cost-Effectiveness of Prasugrel vs. Clopidogrel in ACS
  67. Optimal Dosing of Antiplatelet Therapy in Patients With ACS Undergoing an Early Invasive Strategy: Insight from CURRENT-OASIS7 Trial
  68. Clopidogrel: Current OASIS7 - Double Is Better !!
  69. The Nuances of Superiority and Non-Inferiority Trials: Design Considerations, Choice of Endpoints, Cost Effectiveness Analyses
  70. Randomized Trials vs. Observational Registries: Strengths and Weaknesses
  71. Structural Heart Disease
  72. Updated Antiplatelet Therapy After PCI; Prasugrel, AZD6140..;The Future We Can Expect in Routine Practice?
Conference Slides
Category